Cancer therapy shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in trial
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, ...
21 hours ago
0
0